Immix Biopharma, Inc.
IMMX· Nasdaq
Released Mar 25, 2026, after the close
10-K filed Mar 25, 2026, 84 days after period end · 0001493152-26-012714
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$10.65M | -$4.81M | -$5.09M | -$3.80M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2025 · filed Mar 25, 2026 · 84 d after period end
2.0% from the close of Mar 25, 2026 to the close of Mar 26, 2026, the first after the release.